New combo aims to wipe out hidden ovarian cancer after chemo
NCT ID NCT05739981
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 21 times
Summary
This study tests whether adding an experimental drug (IMNN-001) to standard chemotherapy and bevacizumab can better eliminate leftover cancer in people with advanced ovarian, fallopian tube, or peritoneal cancer. About 30 newly diagnosed participants will be randomly assigned to receive the standard treatment with or without IMNN-001. The main goal is to see if the combination leads to less residual disease detected during a second-look surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Medicine SKCCC
COMPLETEDBaltimore, Maryland, 21231, United States
-
Memorial Sloan Kettering Cancer Center
ACTIVE_NOT_RECRUITINGNew York, New York, 10065, United States
-
OU Health, Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Email: •••••@•••••
Contact
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.